Eli Lilly and Company (NYSE:LLY) & MediciNova (NASDAQ:MNOV) Financial Analysis

MediciNova (NASDAQ:MNOV) and Eli Lilly and Company (NYSE:LLY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for MediciNova and Eli Lilly and Company, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1	1	4	1	2.71
Eli Lilly and Company	1	4	24	1	2.83

MediciNova currently has a consensus target price of $7.75, suggesting a potential upside of 452.39%. Eli Lilly and Company has a consensus target price of $1,416.64, suggesting a potential downside of 1.74%. Given MediciNova’s higher probable upside, equities analysts plainly believe MediciNova is more favorable than Eli Lilly and Company.

Institutional and Insider Ownership

9.9% of MediciNova shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares MediciNova and Eli Lilly and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Eli Lilly and Company	31.90%	86.76%	22.03%

Earnings and Valuation

This table compares MediciNova and Eli Lilly and Company”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410,000.00	168.43	-$12.00 million	($0.21)	-6.68
Eli Lilly and Company	$65.18 billion	20.81	$20.64 billion	$30.81	46.79

Eli Lilly and Company has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

MediciNova has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Summary

Eli Lilly and Company beats MediciNova on 10 of the 14 factors compared between the two stocks.

About MediciNova

MediciNova, Inc. (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions. Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.